Lifeward Ltd.
Company Information
Industry Orthopedic, Prosthetic & Surgical Appliances & Supplies
SIC Code 3842
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation Israel
Business Address 200 DONALD LYNCH BLVD., MARLBOROUGH, MA, 01752
Mailing Address 200 DONALD LYNCH BLVD., MARLBOROUGH, MA, 01752
Phone 15082511154
Fiscal Year End 1231
EIN 000000000
Financial Overview
FY2025 FY
$25.66M
Revenue
-$19.91M
Net Income
$30.49M
Total Assets
$14.49M
Total Liabilities
$68.17M
Stockholders' Equity
$6.75M
Cash & Equivalents
$-17.16
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | March 27, 2026 | View on SEC |
| 3 Initial insider ownership report | March 27, 2026 | View on SEC |
| 3 Initial insider ownership report | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 27, 2026 | View on SEC |
| 3 Initial insider ownership report | March 27, 2026 | View on SEC |
| 8-K Current report of material events | March 25, 2026 | View on SEC |
| 8-K Current report of material events | March 20, 2026 | View on SEC |
Annual Reports
10-K March 18, 2026
- Lifeward achieved 22% revenue growth to $28.5 million in 2025, primarily from NeuroSense device sales and platform subscriptions.
- The company significantly improved its financial health by raising $20 million, increasing cash to $18.2 million, and turning working capital positive.
Material Events
8-K Acquisition March 25, 2026
High Impact
- Completed $25 million acquisition of Oratech Pharma to integrate medical treatments with robotics hardware.
- Expanded board of directors from five to seven members to facilitate leadership integration.
8-K Legal Issue March 20, 2026
High Impact
- Lifeward is actively reviewing options to regain Nasdaq compliance.
- The core business and products of Lifeward are not directly impacted by this governance issue.
8-K Financial Distress March 2, 2026
High Impact
- Lifeward Ltd. successfully avoided delisting from Nasdaq by executing a 1-for-12 reverse stock split.
- Maintaining a Nasdaq listing provides credibility, visibility, and access to a broader investor base.
8-K Financial Distress February 19, 2026
High Impact
- Lifeward Ltd. secured a new, high-interest secured loan from Oramed Pharmaceuticals, Inc.
- The loan initially provides $525,000, with potential to increase to $1.5 million based on shareholder approval.
8-K Financial Distress February 9, 2026
High Impact
- Lifeward Ltd. secured an extension from Nasdaq to regain compliance with the minimum bid price requirement, pushing the deadline to August 3, 2026.
- Shareholders have approved a 1-for-12 reverse stock split, which the company is considering implementing to artificially boost its share price.
8-K Strategy Change January 6, 2026
High Impact
- Shareholders approved a potential reverse stock split to increase share price and meet listing requirements.
- Shareholders also approved increasing the total number of authorized shares, providing flexibility for future fundraising.
Related Companies
Companies in the same industry (SIC: 3842)
LAKELAND INDUSTRIES INC
LAKE Orthopedic, Prosthetic & Surgical Appliances & Supplies
Inogen Inc
INGN Orthopedic, Prosthetic & Surgical Appliances & Supplies
LogicMark, Inc.
LGMK Orthopedic, Prosthetic & Surgical Appliances & Supplies
CollPlant Biotechnologies Ltd
CLGN Orthopedic, Prosthetic & Surgical Appliances & Supplies
ESTABLISHMENT LABS HOLDINGS INC.
ESTA Orthopedic, Prosthetic & Surgical Appliances & Supplies
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.